News & Insights

As we continue to grow our business in the US, we are thrilled to announce that Rami Levin is joining our board. Rami’s extensive leadership experience in Life Sciences will be instrumental in providing strategic advice to our biotech community.

Rami Levin is a seasoned biotech executive with nearly 30 years of leadership experience across the pharmaceutical and biotechnology sectors. He has led private and public companies, managed large P&Ls, driven scale-ups, and raised transformative capital. Rami has held prominent roles, including CEO of ImStem Biotechnology and Saniona, as well as President of Sobi Inc., where he built the North American team from the ground up, growing it to over 300 employees and generating $500M+ in annual revenue. He is also the Founder and CEO of The Outcomes Group, specializing in strategy and executive development for biotech leaders.

We are excited to have Rami’s expertise guiding us as we continue to support emerging biotech's in their growth journeys.

Last year, we had a big focus on AI and its applications in life sciences, and one particularly exciting subset of that is “digital twins.” These are virtual replicas of real-world systems, processes, or even patients, powered by advanced simulations and data analytics. By modelling how a disease progresses in a virtual patient, digital twins can help researchers predict treatment outcomes more accurately, identify potential side effects earlier, and reduce the risks and costs associated with clinical trials.

In the life sciences industry, digital twins have the potential to reduce data disparities, especially for underrepresented patient groups, by simulating diverse patient populations and testing interventions in virtual settings. This means clinical trials could become more inclusive, treatments more personalised, and drug development timelines potentially shorter. It’s a powerful concept that may pave the way for a new era of precision medicine and more efficient R&D.

Bayer is among the early adopters of digital twin technology, forming a collaboration in 2023 with Atlis Labs to help accelerate and improve cancer trials using AI-generated digital twins. Founded in 2019, Atlis intends to advance precision medicine by partnering with healthcare systems to train and validate its AI models on historical de-identified patient data. The company trains its models on historical real-world data to predict standard-of-care patient outcomes so that in a clinical trial, they can predict what a patient’s outcome would be if they got the standard-of-care treatment.

We’ve had the privilege of collaborating with some truly ground-breaking companies in this space, supporting their innovation by providing strategic advice on talent and operational alignment. Often, we find that existing processes don’t align seamlessly with the demands of the tech market, making tailored consultation essential.

One key area we emphasise when advising clients investing in technology is leadership. A fundamental question we pose is: Does your organisation have an executive in place who can safeguard and maximise your tech investment? Despite the rapid adoption of technology, there remains a notable shortage of tech-focused executives or board members equipped to provide the necessary oversight. Interestingly, many companies wouldn’t think of operating without a scientific advisory board, yet they are often willing to proceed with less oversight for the technology driving their innovation alongside the science.

Equally important is ensuring a robust leadership structure. We frequently ask our clients: Has your leadership team ever managed a tech-driven team? Across the industry, interdisciplinary teams are becoming the norm, blending expertise from diverse fields such as AI, data science, and biology. Many of our clients seek guidance on upskilling their leaders to effectively manage these complex, cross-functional teams. By fostering strong leadership capable of bridging these disciplines, organisations can create a communicative, high-performing, and innovative environment that drives success.

As the industry begins to explore digital twins in greater depth, we at GENerX Life see tremendous opportunities to connect organisations with the talent they need to shape and lead these breakthroughs. What excites you most about the potential of digital twins in healthcare? Let us know in the comments!

We’re delighted to welcome Barbara Greutter as our newest Board Member at GENerX Life. Barbara brings deep expertise in HR leadership, M&A integration, and organisational transformation.

A seasoned CHRO and strategic HR leader, Barbara has over 20 years of experience advising executive teams across Pharma, Biotech, Tech, and Consulting. She has played a pivotal role in scaling early-stage companies, driving market expansions, and leading HR transformations that fuel business success.

Her expertise spans large-scale M&A integrations, post-merger transformations, and major restructuring initiatives across multiple countries. She has also led complex divestitures, emerging market expansions, and executive leadership development—helping HR leaders build high-performing, future-ready teams.

At GENerX Life, we believe HR is at the core of business success. With Barbara’s strategic insight and hands-on experience, we are enhancing our ability to help HR leaders and executives navigate growth, transformation, and talent strategy—ensuring their organisations are built for the future.

Another year of life sciences innovation is on the books. The U.S. FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new therapeutics in 2024, slightly down from 55 in 2023. Despite the dip, several first-in-class breakthroughs and regulatory shifts - particularly around artificial intelligence - set the tone for an exciting future. Below is a comprehensive look back at the year’s highlights and a brief preview of what 2025 might hold.

Contents

1. Breakthrough Therapies and “Firsts”

2. AI in the Regulatory Spotlight

3. Additional Market Insights

• Small Molecules vs. Biologics & Hybrids

• Therapeutic Area Breakdown

• Funding and M&A Trends

4. Talent and Leadership Takeaways

• Need for Interim Expertise

• Data-Driven Hiring and Assessments

• Interdisciplinary Expertise

• Leadership Coaching and Development

• Robust Investment and VC Strategies

5. Looking Ahead to 2025

• Continued AI Evolution

• Focus on “De-risked” Assets

• M&A Resurgence

• New Modalities and Breakthroughs

• Increased Focus on Talent and Leadership

6. Final Thoughts

Breakthrough Therapies and “Firsts”

Cobenfy (xanomeline/trospium) for Schizophrenia

Co-developed by Karuna and Bristol Myers Squibb, Cobenfy represents the first novel mechanism of action in schizophrenia therapy in decades. By dual-targeting M1 and M4 muscarinic acetylcholine receptors, it addresses schizophrenia symptoms in a fundamentally different way than standard antipsychotics. Initial clinical data suggest substantial improvements in symptom severity, with analysts projecting peak annual sales exceeding $3 billion—testament to the unmet need and the product’s anticipated market impact.

Rezdiffra (resmetirom) for NASH

Marking a significant milestone for patients with non-alcoholic steatohepatitis (NASH), Madrigal’s Rezdiffra earned its place as the first FDA-approved therapy in this disease area. A thyroid hormone receptor-beta agonist, Rezdiffra has demonstrated moderate but meaningful benefits to liver health. With patient numbers expected to soar in the coming years, analysts foresee a potential peak sales figure of $3.3 billion—indicative of the medical community’s eagerness to adopt a new therapeutic option for a long-overlooked disease.

Amtagvi (lifileucel) for Advanced Melanoma

Amtagvi introduces the first-ever tumour-infiltrating lymphocyte (TIL) therapy to secure FDA approval for advanced melanoma. Developed by Iovance Biotherapeutics, this “living therapy” harnesses the body’s own immune cells to target and destroy tumour cells. Though it presents certain logistical and toxicity challenges, the therapy’s demonstrated capacity to induce lasting responses underscores the growing promise of cell-based approaches in combatting aggressive solid tumours.

Alyftrek (deutivacaftor, vanzacaftor, tezacaftor) for Cystic Fibrosis

Vertex’s Alyftrek is a next-generation triple combination therapy that pushes forward cystic fibrosis (CF) treatment. By attacking the disease’s underlying genetic defect from multiple angles, Alyftrek has shown the potential to enhance lung function and overall quality of life for CF patients. Analysts predict peak sales to exceed $8.3 billion, further establishing Vertex’s leadership in this space and highlighting the persistent demand for transformative therapies that address complex, multi-faceted diseases.

AI in the Regulatory Spotlight

Evolving FDA Approach

CDER has observed a substantial rise in drug application submissions that incorporate AI across the full product lifecycle—nonclinical, clinical, post-marketing, and manufacturing. AI also increasingly features in Digital Health Technologies (DHT) and Real-World Data (RWD) analytics, signalling how pervasive machine learning is becoming.

In response to this, the FDA announced plans to issue draft guidance in 2025 titled “Considerations for the Use of Artificial Intelligence to Support Regulatory Decision Making for Drug and Biological Products,” which will provide recommendations to industry on using AI to produce information or data intended to support regulatory decision-making regarding drug safety. This guidance has been informed by:

• Feedback from a December 2022 expert workshop hosted by Duke

• Over 800 comments on a May 2023 discussion paper on AI use in drug development

• CDER’s experience with over 500 AI-related submissions from 2016 to 2023

• A public workshop held in August 2024 discussing guiding principles for responsible AI use in drug development

Further to this, the FDA has newly established a CDER AI council which is tasked with:

• Coordinating internal AI capabilities.

• Developing AI policy for regulatory decision-making.

• Promoting consistency in assessing AI’s impact on drug safety, effectiveness, and quality.

• Facilitating trustworthy AI use in regulatory, research, and administrative efforts.

MHRA’s Proactive Stance

Here at home, the UK’s MHRA has also published draft guidance on AI-driven drug development. Though we haven’t formed a standalone council, these guidelines aim to ensure patient safety and data integrity in an era of rapid technological advancement.

Additional Market Insights

Small Molecules vs. Biologics & Hybrids:

• Small Molecules: Despite the growing variety of drug modalities, small molecules continued to dominate with 64% of approvals in 2024.

• Biologics: Represented 32% of approvals, including 10 new monoclonal antibodies and 3 bispecific antibodies.

• Oligonucleotides: There were 2 approvals for these innovative therapeutics in 2024. Oligonucleotides are short DNA or RNA molecules designed to target specific genetic sequences, enabling precise modulation of gene expression. This is an exciting step as the ability to target the genetic underpinnings of a disease means these therapies can potentially address diseases deemed “undruggable” by small molecules or antibodies, opening up a wave of new treatments.

Therapeutic Area Breakdown

Oncology unsurprisingly led the field with 15 approvals, including several first-in-class therapies. Dermatology and non-malignant hepatology each saw 6 approvals, highlighting a growing interest in diseases that affect large patient populations and can have major quality-of-life impacts. Cardiology also saw significant progress, with 5 new therapies being approved last year.

Funding and M&A trends

We saw some interesting funding trends in 2024 including venture capital favouring more de-risked companies, with VCs writing fewer but larger checks. A prime example (although in 2025 as opposed to 2024) is Verdiva Bio’s recent $410m Series A, an extraordinary amount for an early-stage round, to develop a weekly-dosed oral GLP-1 agonist.

This is only one example of the recent shift in investment patters we’ve seen, where capital has disproportionately been going to more de-risked companies with a fast path to the clinic, and smaller discovery-stage ventures have struggled to secure backing.

Talent and Leadership Takeaways

Within our business, we have seen a number of trends amongst our clients in 2024 which we break down below:

Need for Interim Expertise

Amid challenging market conditions, biotechs are increasingly turning to interim support. With financial constraints, talent shortages, and market volatility, interim professionals offer critical flexibility, reduced risk, and specialised expertise to drive project development. This trend highlights the sector's need for agile and cost-effective leadership solutions.

Data-Driven Hiring and Assessments

As operational costs rise, the consequences of hiring failures have become even more significant (and potentially terminal) for companies. Many traditional hiring methods, proven to be ineffective, are being phased out in favour of data-driven processes. By analysing internal and external behaviours, personalities, and cultural alignment, companies can ensure their hires are future-proof, enhancing retention and fostering robust company cultures.

Interdisciplinary Expertise

The importance of interdisciplinary talent is one trend we have seen clearly over 2024, especially with the increased prevalence of AI. Organisations are finding that a purely technical background in machine learning is no longer sufficient; teams must also incorporate deep domain knowledge in biology, genetics, and chemistry to accurately interpret complex datasets and design models that align with real-world pathophysiological processes. This level of integration is critical to ensuring AI tools actually advance scientific understanding and patient outcomes.

At the same time, the field of machine learning itself remains dauntingly diverse, requiring solid foundations in statistics, linear algebra, and data engineering, alongside specialised skills in distributed computing and project leadership. Bringing the data science and life sciences worlds together calls for leaders who can shape an overarching vision and foster effective collaboration between experts on both sides. In 2024 “ideal hires” have been those comfortable translating biology into computational frameworks, guiding AI development, and orchestrating the cross-functional teams that move discoveries forward.

Leadership Coaching and Development

With the rapid evolution of business landscapes - spurred by increased regulation, technological advancements, and changing work environments - companies are prioritising leadership development. Empowering current and emerging leaders with the skills to navigate complexity and drive innovation is no longer optional but essential for long-term success.

Robust Investment and VC Strategies

Developing a clear and robust investment strategy is vital in today’s cautious financial climate. Many biotechs are still seeking funding, yet even companies with strong data sometimes struggle to secure the right backing. Companies must refine their investment strategies early, with a particular focus on aligning leadership, operating models, and commercialisation plans. VCs are increasingly investing in company creation, exercising greater control, making it essential for later-stage companies to present a compelling case for funding and scalability.

Looking Ahead to 2025

Continued AI Evolution

With the FDA’s draft AI guidance on the horizon and the MHRA’s parallel efforts, we can anticipate closer regulatory scrutiny on machine learning-based processes. Companies that proactively invest in robust AI frameworks and transparent data practices may gain a competitive edge.

Focus on “De-risked” Assets

The trend of venture capital persisting in backing later-stage projects or those with clear pathways to the clinic is likely to continue in 2025. As a result, early-stage start-ups might partner more aggressively or streamline pipelines to demonstrate feasibility more quickly.

M&A Resurgence

Coming out of the JP Morgan Healthcare Conference this year, the industry is getting ready for a heavier year of M&A activity compared to last, as there is the potential for less antitrust scrutiny under President-elect Donald Trump. Roche’s CEO Teresa Graham said at the conference that the company has access to $10 billion per year for M&A activity, and they’re not the only company that has indicated their desire to acquire transformative assets.

New Modalities and Breakthroughs

In 2024, we have seen pockets of investor excitement, such as that seen in the obesity market, with the intense race to have the best drug on the market. What the trend of 2025 will be remains to be seen, but with AI playing an increased role in drug discovery, there could be some surprise breakthroughs that nobody saw coming.

Increased Focus on Talent and Leadership

As we move into 2025, the key talent and leadership themes that emerged over the past year show no signs of slowing. Interdisciplinary expertise - particularly in AI, machine learning, and the life sciences - will remain a critical differentiator, driving continued demand for professionals who can integrate robust data analytics with specialised domain knowledge. Data-driven hiring and interim leadership solutions are likewise poised for further growth, offering the agility and precision needed in an increasingly competitive environment. Meanwhile, leadership development and investor engagement will become even more central as biotechs strive to demonstrate both operational excellence and scalability.

Final Thoughts

Although 2024 saw a slight decrease in FDA approvals, the scope and complexity of new therapeutics, from TILs to triple combinations to AI-driven submissions, demonstrate an industry in the midst of profound transformation. With regulatory agencies increasing their focus on AI and the investment community emphasising de-risked assets, both scientific acumen and strategic agility will define which players thrive in 2025 and beyond.

At GENerX Life, we are positioned again this year to help our clients adapt and excel amid these evolving dynamics. Weather it’s utilising our expert advisory board to help drive an AI strategy, securing top-level interdisciplinary talent, or get immediate support from our interim solutions, we’re excited to be able to help our clients thrive in 2025.

London, 11 June 2024 - GENerX Life, the Life Science Search, Interim, and Leadership Development firm, is pleased to announce that Claes Zackrisson is joining as Managing Director. Claes will lead international expansion and future growth, drawing on almost 20 years of experience working with emerging and established companies in the Life Science industry. Claes has expertise established by leading boutique firms based in Paris and London. He has successfully led large recruitment projects, delivered on hundreds of assignments ranging from director to C-level positions, and contributed to the development and execution of development centres, leadership development, and individual coaching. Claes is a Swedish native, speaks fluent English and French, and has worked with organisations worldwide.

"Claes's deep expertise and proven leadership in the Life Science sector make him a remarkable addition to our team," said Jack Corbet CEO. "His extensive experience and strategic vision will be invaluable as we continue to deliver impactful solutions to our clients. With Claes at the helm, we are excited to push the boundaries of innovation and drive significant growth for our clients and GENerX globally."

“I’m thrilled to welcome Claes to GENerX Life” said Matt Price, Chair and Co-founder. “Claes’s expertise reinforces our commitment to providing innovative solutions for our clients and helping them to deliver on their strategic goals.”

Claes Zackrisson commented, “Joining GENerX Life as Managing Director is a tremendous honour and an exciting opportunity. I'm deeply impressed by the company's commitment to pushing the boundaries and delivering impactful solutions to improve lives. I'm eager to collaborate with the talented team at GENerX Life to drive innovation, foster growth, and make a meaningful difference in the world. Together, I'm confident we'll achieve great things and lead the way in shaping the future of the Life Science industry.”

Introduction

The obesity epidemic has reached alarming proportions globally, with over 650 million people affected, leading to significant health challenges and economic burdens. In response to this crisis, pharmaceutical companies have increasingly turned their focus towards developing innovative obesity treatments. The market for obesity drugs and therapies is predicted to be worth around $150 billion by 2030, making it a  lucrative yet challenging sector. As the industry continues to evolve, pharmaceutical companies face a unique set of staffing and leadership challenges. This article explores these challenges and offers ideas on how to address them.

Specialised Expertise

Developing obesity drugs requires a multidisciplinary approach, involving professionals from various fields such as pharmacology, endocrinology, nutrition, and behavioral psychology. Finding and retaining top talent with expertise in these areas can be a significant challenge. It's crucial to hire professionals who not only understand the scientific aspects but also appreciate the complexities of obesity as a disease.

Solution: Establish partnerships with academic institutions and research organisations to access a pool of experts. Offer attractive compensation packages and opportunities for career growth to retain top talent.

Regulatory Hurdles

The pharmaceutical industry is heavily regulated, and bringing obesity drugs to market involves navigating a complex web of regulatory requirements. Obesity treatments may involve unique safety and efficacy challenges, which require a deep understanding of the evolving regulatory landscape.

Solution: Invest in regulatory affairs teams with experience in the development and approval of obesity drugs. Foster open communication with regulatory agencies to ensure compliance and streamline the approval process.

Market Demand and Competition

The demand for effective obesity treatments is enormous, as evident from the rapid success of drugs like Wegovy. However, the competitive landscape is intense, with numerous pharmaceutical companies vying for market share. This competition can put pressure on leadership to stay ahead in drug innovation while managing cost-effectiveness.

Solution: Foster a culture of innovation and research within the company.  Encourage cross-functional teams to collaborate on novel approaches to obesity treatment. Continuously monitor the competitive landscape to adapt to changing market dynamics.

Long-Term Efficacy and Safety

While drugs like GLP-1RAs show promising results in clinical trials, concerns about long-term efficacy and safety persist. Leadership must address these concerns and ensure that treatments provide lasting benefits without unforeseen side effects.

Solution: Invest in long-term clinical studies to address safety and efficacy concerns comprehensively. Collaborate with healthcare providers to monitor patients post-treatment and gather real-world data.

Ethical Considerations

Obesity is a complex issue with social, economic, and ethical dimensions. Leaders in pharmaceutical companies must navigate public perception and ethical concerns related to obesity drug development.

Solution: Engage in transparent communication with the public and healthcare professionals about the benefits and limitations of obesity treatments. Collaborate with advocacy groups to raise awareness about the disease and the need for effective treatments.

Maintaining a Patient-Centric Approach

Obesity is a deeply personal and often stigmatised condition. To be successful, pharmaceutical companies must remain committed to a patient-centric approach, understanding the unique challenges faced by individuals struggling with obesity.

Solution: Establish patient advisory boards to gain insight into the experiences and needs of patients. Ensure that company leadership embodies a culture of empathy and commitment to improving patients' lives.

Conclusion

The pharmaceutical industry's focus on obesity drug development presents significant opportunities and challenges. Overcoming these staffing and leadership challenges is crucial to making a positive impact on the lives of millions affected by obesity. By fostering a culture of innovation, attracting top talent, and maintaining a patient-centric approach, pharmaceutical companies can contribute to the transformation of the obesity landscape in the coming years. While the road ahead is not without obstacles, the potential to improve lives and combat this global epidemic makes the journey worthwhile.

Obesity has reached epidemic proportions worldwide, affecting some 650mn people and posing significant health challenges and economic burdens. Unsurprisingly, it has also become a key focus area for the life sciences industry, with the market for obesity treatments and individual therapies predicted to be worth around $150 billion by 2030.

Traditionally, obesity treatments have focussed on changing dietary habits and encouraging exercise. However, a greater understanding of the condition has led to promising advancements in obesity drug development, with the glucagon-like peptide-1 (GLP-1RA) emerging as a   breakthrough therapy and attracting significant investment from large pharma and biotech players.

These therapies have revolutionised the approach to obesity treatment because they can target multiple mechanisms associated with obesity, providing a comprehensive approach to weight management. They have also demonstrated significant efficacy in weight reduction and glycemic control.

GLP-1RA is a naturally occurring hormone released by the gut in response to food consumption. It plays a crucial role in glucose metabolism, appetite regulation and satiety. It functions by binding to specific receptors in the brain, pancreas and gastrointestinal tract, thereby enhancing insulin secretion, suppressing glucagon release, slowing gastric emptying and reducing appetite. Clinical trials have shown that   GLP-1RAs promote weight loss while improving metabolic parameters, including blood glucose levels, insulin sensitivity and lipid profiles. Plus, they reduce food intake, enhancing satiety and increase energy expenditure.

These therapies also have demonstrated a favourable safety profile in clinical trials, with the most common side effects being transient gastrointestinal symptoms. Long-term studies have indicated no major safety concerns, although careful monitoring is still necessary. Additionally, GLP-1RAs have been associated with a decrease in cardiovascular risk factors, such as blood pressure and inflammatory markers.

As such, they are a major step forward in the treatment of obesity and will usher in a new era of weight management. The opportunity they represent for the industry is also significant. Demand for Novo Nordisk’s Wegovy – which only received FDA approval in mid-2021 – is such that the manufacturer is struggling to keep up with surging demand. Despite this, the drug achieved $900 million in sales in 2022 alone, and it is clear that the potential market for therapies that can improve the lives of millions affected by this complex condition is very significant. Whilst understanding obesity as a disease and not just a lifestyle decision has been an important step in tackling the global obesity epidemic, Sarah Bosley argues in this article in The Guardian Highlights (https://www.theguardian.com/commentisfree/2023/apr/25/skinny-jab-obesity-junk-food-britain-tax) that a`skinny jab`is no quick fix for obesity nor is it a reason to let junk food companies off the hook. She goes on to note that the weekly injections have to be combined with a low-calorie diet and exercise and cautions that once people stop injecting them the pounds can pile back on. I believe that the industry can dramatically change the obesity landscape in the coming years and that it’s a healthy sign that the new obesity treatments are a source of debate and discussion. There are still some major hurdles to cross including regulatory issues and potential efficacy and safety concerns butthere’s no doubt that these new therapies can be a game changer for patients.

The life sciences sector, encompassing pharmaceuticals, Biotech, and MedTech, has been experiencing robust growth, with the sector's underlying value pegged at a staggering US$2.83 trillion. This growth, which has been sustained even during the pandemic, especially with the surge in demand for COVID-19 vaccines, is driving life sciences companies to recalibrate their strategies. Here's a deep dive into the current state and future prospects of the biotech/life sciences market:

Portfolio Strategies and Growth Trajectories

Companies are actively shifting their portfolio strategies to sustain and enhance their growth trajectories. This involves a mix of acquisitions, divestitures of non-core assets, increased investments in R&D, and a rapid embrace of digital and data technologies.

Innovation and Collaboration

To maintain their growth, life sciences companies are doubling down on innovation. This includes expanding platforms like gene and cell therapies, exploring new platforms such as mRNA, and developing novel medicines like antibody drug conjugates (ADCs).

Digital Transformation

Digital technologies, including AI, automation, and blockchain, are being scaled up to create efficiencies. These technologies are expected to lower development and manufacturing costs and expedite drug research and development.

Regulatory Challenges

With governments worldwide tightening regulations and demanding greater transparency in drug reviews, approvals, pricing, and reimbursement, life sciences organisations are striving to comply while still catering to patient needs.

Supply Chain Resilience

The pandemic and geopolitical conflicts have underscored the need for flexible and agile supply chains. Companies are moving from rigid planning to designing supply chains that can swiftly adapt to changing conditions.

Patient-Centricity

Patients and healthcare providers are increasingly demanding innovative and effective treatments. Catering to these demands requires not just new technologies but also a heightened focus on patient-centricity and the advancement of value-based care.

Evolving Portfolios and Value Creation

Life sciences companies are exploring various models and portfolio choices. This includes the development of potential "blockbuster" medicines, pursuing next-generation therapies, and focusing on diversification.

R&D Innovations

Investments in R&D are pivotal for the sector's growth. mRNA technology, for instance, is seen as a game-changer. Unlike traditional vaccines, mRNA vaccines use genetically engineered molecules, offering a quick design and scalability advantage.

Next-Generation Therapies

Research into next-generation therapies, including gene editing, is gaining momentum. The discovery of CRISPR/Cas9 has opened up possibilities for eliminating inherited diseases.

Real-World Evidence (RWE)

RWE, which provides clinical insights based on real-world data, is becoming increasingly important. It aids in understanding disease progression, monitoring patient safety, and assessing clinical and cost-effectiveness. In conclusion, the biotech/life sciences sector is at an inflection point, with companies actively redefining their strategies to navigate the challenges and capitalise on the opportunities. As they continue to innovate, collaborate, and transform, the future looks promising for both the industry and the patients it serves.

Source: Deloitte's "2023 Global Life   Sciences Outlook"